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ABSTRACK 
Introduction: New breast anticancer compound N-
(phenylcarbamothioyl)-benzamide have been synthesized, initiated 
with molecular modeling in silico which is docking between test 
compounds with SIRT-1 receptor PDB code: 4I5I to predict the 
bonding of test compounds with receptors. Methods: The compounds 
are synthesized from benzoyl chloride reaction with N-phenylthiourea. 
The molecular structure is confirmed using FTIR, 
1
H-NMR, 
13
C-NMR 
and Mass Spectra. Anticancer activity is tested in vitro against human 
breast cancer cells (T47D) using an MTT assay. Result: RS (Rerank 
Score) value and anticancer activity of test compound obtained are higher than Hydroxyurea 
as the reference compound. The Value of IC50 N-(phenylcarbamothioyl)-benzamide is 0.53 
mM (T47D cell) and 49.40 mM (Vero cel) and also  IC50 Hydroxyurea is 4.58 mM (T47D 
cells). It is predicted that the mechanism of action of these new compounds is targeted cell 
because it has toxic effect on cancer cells and is not toxic in normal Vero cells. Conclusion: 
This new compound are highly potential as an anticancer agent against the human breast 
carcinoma cell line (T47D). 
 
KEYWORDS: N-(phenylcarbamothioyl)-benzamide, anticancer, T47D cell, SIRT 1. 
 
INTRODUCTION 
Cancer is one of the major causes of death in developing countries and also worldwide. In 
Indonesia, cancer becomes the third largest contributor to death after heart disease. Since 
2007 breast cancer has reached first ranks for in-patients in hospitals, followed by cervical 
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cancer. Thiourea is a compound containing sulfur and nitrogen atoms whose chemical 
structures are similar to the urea compound already used today as an anticancer, including 
hydroxyurea, nitrosourea and 5-fluorouracil.
[1]
 
 
Resistance/intolerance has been reported against hydroxyurea in patients with essential 
thrombocythaemia.
[2]
 The clinical use of hydroxyurea begins to diminish, but in biochemical 
research and development of the anticancer drug hydroxyurea is used as a DNA replication 
inhibitor.
[3]
 The research data show that hydroxyurea activity is not maximum because it is 
hydrophilic with poor membrane penetration capability so it is necessary to develop new 
anticancer drugs of urea and thiourea derivatives which is more lipophilic with better 
membrane penetration so that its activity is more potent. Pirrie, 2012, has synthesized and 
evaluated the anticancer activity of thiourea derivatives, as 1-(4-acetamidophenyl)-3-(4-tert-
butylbenzoyl) thiourea which is later named Tenovin-1. These compounds are known to 
increase p53 protein levels in vitro (inhibits SIRT1).
[4]
 Widiandani, 2016, has also proven 
breast anticancer activity (T47D cells) of the N- (allylcarbamothioyl)benzamide compound.
[5]
 
 
In this study, a new compounds N-(phenylcarbamothioyl)-benzamide is obtained with the 
presence of phenyl and benzoyl rings enhancing the lipophilic and electronic nature of the 
compound which in turn will improve the bonding of drugs and receptors. Breast cancer cell 
T47D is used to express the mutated p53 protein initiated with activity predictions by 
molecular modeling in silico, docking test compound with Histon deacetylase SIRT1 
inhibitor code of PDB: 4I5I. This receptor has an important role in the growth of tumor 
cells.
[6]
 The test compounds are synthesized from N-phenylthiourea with benzoyl chloride 
using acyl nucleophilic substitution reactions.
[7]
 The compounds resulted from the synthesis 
are then identified in structures with IR spectrophotometers, 
1
H-NMR spectrometers, 
13
C-
NMR and mass spectrometers.
[8]
 
 
The anticancer activity of the test compound is determined by cytotoxic test using MTT assay 
(3-(4,5-dimethyltiazole-2-yl) -2,5-diphenyltetrazolium bromide) in vitro on T47D breast 
cancer cells and normal Vero cells. The results of anticancer activity test on T47D cells are 
IC50 compared with Hydroxyurea as the reference compounds, also observed in normal cell 
Vero. The results of this study is expected to obtain a candidate for a new anticancer drug 
from thiourea derivatives that have potent anticancer activity on breast cancer cells T47D.
[9]
 
This study will proceed with the synthesis of N-(phenylcarbamothioyl)-benzamide 
derivatives and molecular mechanisms, prior to preclinical and clinical trials. 
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MATERIALS AND METHODS 
WORK PROCEDURES 
Molecular Modeling 
Predicting activity with molecular modeling of N-(phenylcarbamothioyl)-benzamide by 
docking with Histon deacetylase SIRT1 inhibitor PDB code: 4I5I, continued with using the 
MVD 5.5 software. Hydroxyurea is used as a reference compound.
[10]
 
 
Test Compunds Synthesis 
The Synthesis of N-(phenylcarbamothioyl)-benzamide 
In a round flask, N- phenylthiourea is mixed with tetrahydrofuran and TEA. a benzoyl 
chloride solution in tetrahydrofuran is added into the mixture, bit by bit through a dropping 
funnel over the ice bath, stirred with a magnetic tool. The mixture is refluxed and stirred in a 
water bath and in TLC every hour. The reaction is terminated whenever a single stain in TLC 
is formed. After the termination, THF is evaporated on the rotary evaporator proceeded with 
recrystallization.
[5]
 
 
The identification of the compound structure of the synthesis results is conducted based on 
the results of the examination: Infrared, 
1
H-NMR, 
13
C-NMR and MS. 
 
Cytotoxic Test On T47D Breast Cancer Cells and Normal Vero Cells 
Anticancer activity is performed in vitro using T47D the breast cancer cells. 5 mg of test 
compound in 100 μl DMSO is dissolved to obtain 50.000 μg / mL concentration. The mother 
liquor is diluted gradually with RPMI culture medium for T47D cells to obtain a series of 
standard working solution. T47D cancer cell culture is prepared in microplate with 96 wells 
in a form of a cell suspension  used in the experiment with a density of 10,000 cells / pitting. 
Empty wells are set on the plate for media control and afterwards CO2 5%  incubator  is added 
for 24 hours. 
 
After incubated, the plate is removed and the media is discarded by 180 degrees reversion . 
After washed with PBS 100 μL for each well, then PBS was discarded by reversing the plate 
180 degrees. A total of 100 μL of standard working solution, positive control and solvent 
control are included in microplate pours. Each concentration is replicated three times. Sums 
that do not contain T47D cancer cells are filled with media as media controls. Then incubated 
at incubator 5% CO2 for 24 hours, at 37
0
C. After 24 hours the plate is removed from the 
incubator and the media is discarded. Within each well, 0.5 mg / ml of MTT is added to 100 
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μl / well, then incubated for 3 hours. After 3 hours of incubation, microplate is removed and 
the reaction is terminated by adding 100 μl SDS 10% in 0.1 N HCl to the hole. Microplate is 
wrapped with aluminum paper and incubated for 24 hours at 5% CO2 incubator, then Elisa 
Reader is inserted at λ = 595 nm. With probit analysis we get IC50 values from test 
compound.
[11]
 
 
RESULTS AND DISCUSSION 
 
 
 
 
 
 
(a)                                                                  (b) 
Fig 1. Preparation of protein (a) Histone deacetylase SIRT1 inhibitor code pdb: 4I5I (b) 
selected hole (corresponding arrow) on the 4I5I receptor where interacting ligan and 
receptor (cavity 1). Images are obtained from Molegro version 5.5. 
 
              
(a) PCTB                                                                     (b)  HU 
Fig. 2: 2D pictures show hydrogen bonds (blue dashed-line) and steric interaction (red 
dashed-line) of N-(phenylcarbamothioyl)-benzamide compound (PCTB)  (a), reference 
drug HU (b) with amino acid in SIRT1 binding site. Images are obtained from Molegro 
version 5.5. 
 
Table 1. The results of the docking value as a Rerank Score (RS). 
No Compounds 
RS 
( PDB 4I5I) 
1 PCTB -119.4130 
2 HU -40.0237 
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Table 2: Hydrogen and steric bonds performed by interaction between tested 
compounds and amino acids in binding site of SIRT1. 
N
O 
COMPOUNDS 
AMINO ACIDS 
ALA 
262 
ASN 
346 
ASP 
272 
ASP 
348 
ILE 
270 
ILE 
347 
PHE 
273 
PRO 
271 
SER 
265 
GLY 
263 
VAL 
266 
GLY 
261 
1. PCTB 2S  4S 1H/1S 5S 1H 3S 5S 1S  1s  
2. Hydroxyurea 1S   2H  1H       
Description: H: Hydrogen bond and S: Steric bond (Van der Waals and Hydrophobic) 
 
The RS values describe drug activity in silico. Based on the results of in silico test (table 1) 
obtained the results of RS PCTB: --119.4130 and RS HU: -40.0237. The smaller the RS 
value, the more stable the resulting drug-receptor bonds are, the more predictable the activity 
will be (Hincliffe, 2008).
[12]
 The number and types of amino acids in Table 2 and Figure 2. 
Based on the bonding of drugs and amino acids, the greater the number of hydrogen bonds 
and steric bonds (Van der Waals and Hydrophobic), it can be predicted that the bonds 
between the drug and the receptor will be more stable. 
 
The new compound N-(phenylcarbamothioyl)-benzamide is synthesized from benzoyl 
chloride with N-phenylthiourea in one stage. The synthesized resultcompound is yellow solid 
and in water insoluble substance . The structure of the synthesis compound is identified by 
IR, 
1
H-NMR, 
13
CNMR, and HRMS spectroscopy as follows. 
 
N-(phenylcarbamothioyl)-benzamide. Yield 71% as yellow crystal, m.p. 108
0
C. 
1
H-NMR 
(DMS0-D6, 400 MHz) : δ 7.30 (t, J=7.2 Hz, 1H, Ar-H); δ 7.43 (dd, J=7.2;8.0 Hz, 2H,Ar-H); 
δ 7.54 (t, J=7.2 Hz, 2H, Ar-H); ); δ 7.65 (dd, J=7.2;1.2 Hz, 1H, Ar-H); ); δ 7.69 (d, J=8.0 Hz, 
2H, Ar-H); δ 7.98 (dd, J=7.2;1.2 Hz, 2H, Ar-H); δ 11.56 (s, 1H,O=C-NH-C=S); δ 12.61 (s, 
1H,S=C-NH-CH2); NMR 
13
C (DMSO-D6, 400 MHz) ; δ 124.87 (2C, Ar); δ 126.87 (2C, Ar); 
δ 128.99 (2C, Ar); δ 128.99 (1C, Ar); δ 129.21 (2C, Ar); δ 132.69 (1C, Ar); δ 133.67 (1C, 
Ar); δ 138.53 (1C, Ar); δ 168.83 (1C, C=O); δ 179.65 (1C, C=S). IR (KBr),ν maks (cm-1) : 
1672 (C=O amide) ; 1672&1451 (C=C Ar); 3219&1592 (NH strech sec.amides); 1085&811 
(C=S). HRMS (m/z) C14H11N2OS: (M-H)
-
: 255.0590, Calc. Mass : 255.0592 δ m/z = 0.0002 
< 0.005. 
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Cytotoxic  Activity 
Table 3: Cytotoxic Effect of PCTB compound on T47D Cell Line. 
S .NO 
CONCENTRATION 
(µg/mL) 
ABSORBANCE 
CELL VIABILITY 
(%) 
1 12.5 0.619 87 
2 25 0.609 86 
3 50 0.565 78 
4 100 0.437 57 
5 200 0.336 40 
6 400 0.247 25 
7 CELL CONTROL 0.693 100 
IC50 : 0.53 mM 
 
Table 4: Cytotoxic Effect of Hydroxyurea compound on T47D Cell Line. 
S .NO 
CONCENTRATION 
(µg/mL) 
ABSORBANCE 
CELL VIABILITY 
(%) 
1 31.25 0.621 90 
2 62.5 0.589 84 
3 125 0.554 78 
4 250 0.424 56 
5 500 0.330 40 
6 1000 0.245 25 
7 CELL CONTROL 0.680 100 
IC50 : 4.58 mM 
 
Table 5: Cytotoxic Effect of  PCTB compound on Vero Cell Line. 
S .NO 
CONCENTRATION 
(µg/mL) 
ABSORBANCE 
CELL VIABILITY 
(%) 
1 31.25 0.200 100 
2 62.5 0.197 98 
3 125 0.195 96 
4 250 0.191 92 
5 500 0.187 89 
6 1000 0.183 86 
7 CELL CONTROL 0.200 100 
IC50 : 49.40 mM 
 
Table 6:  RS, IC50 T47D cell  and IC50 Vero cell values of  test  and reference 
compounds. 
Compound RS 
IC50 T47D Cell 
Line 
IC50 Vero Cell 
Line 
PCTB -119.4130 0.53 mM 49.40 mM 
HU -40.0237 4.58 mM - 
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Table 3 to table 5 are the data of the cytotoxic test result on T47D cancer cells and the normal 
cell Vero. The IC50 values of the test compound obtained from probit analysis are better than 
the Hydroxyurea reference compound. There is a corresponding result between the insilico 
and invitro tests of the test compound and the reference compound (Table 6). The better the 
value of the RS (stable bonding of the drug and the receptor) the better the anticancer activity 
is. 
 
The cytotoxic effect of the T47D cells from the test compound could be seen on figure 3. 
   
(a)                                                     (b)                                            (c) 
Figure 3: 
a. T47D cells before given a test compound 
b. T47D cells after given the test compound (dose 500 μg / mL) 
c. T47D cells after given a test compound (dose 1000 μg / mL) 
 
CONCLUSION 
This study concluds that a new compound of N-(phenylcarbamothioyl)–benzamide show in 
vitro anticancer activity against human breast cancer cells (T47D) higher than the anticancer 
drug hydroxyurea. In the in silico study it can be explained that better inhibitory activity is 
associated with higher affinity with SIRT1 binding sites. The value of IC50 N-
(phenylcarbamothioyl)-benzamide is 0.53 mM, is more active than Hydroxyurea which is 
4.58 mM. This new compound is more suitable for binding enzymes compared to 
Hydroxyurea, as it can illustrate better inhibitory activity. It is predicted that the activity of 
this new compound is targeted cell because it has toxic effects on cancer cells and are not 
toxic to normal Vero cells (Vero cell death ˂15%). Further researches are required to 
examine the molecular mechanism of this new compound. 
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